VVOS (Vivos Therapeutics) Beginning Cash Position: $2.03 Mil (As of Mar. 2026)


VVOS Vivos Therapeutics Inc VVOS
43 GF Score
Price $0.48
GF Value $1.15
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Vivos Therapeutics Beginning Cash Position?

Vivos Therapeutics VVOS +0.19% 43 Beginning Cash Position is $2.03 Mil as of Mar. 2026. GuruFocus rates VVOS with a GF Score™ of 43/100 and a GF Value™ of $1.15 (Possible Value Trap). The stock has 6 warning signs investors should review.

Vivos Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2026 was $2.03 Mil.

Vivos Therapeutics's quarterly Beginning Cash Position declined from Sep. 2025 ($4.40 Mil) to Dec. 2025 ($3.09 Mil) and declined from Dec. 2025 ($3.09 Mil) to Mar. 2026 ($2.03 Mil).

Vivos Therapeutics's annual Beginning Cash Position declined from Dec. 2023 ($3.52 Mil) to Dec. 2024 ($1.64 Mil) but then increased from Dec. 2024 ($1.64 Mil) to Dec. 2025 ($6.26 Mil).

Vivos Therapeutics Beginning Cash Position Related Terms

Vivos Therapeutics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Vivos Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivos Therapeutics Beginning Cash Position Chart

Vivos Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial 18.21 24.03 3.52 1.64 6.26

Vivos Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.26 2.34 4.40 3.09 2.03
VVOS
43GF Score
Vivos Therapeutics Inc VVOS
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vivos Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $2.03 Mil mean?
Vivos Therapeutics (VVOS) has a Beginning Cash Position of $2.03 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Vivos Therapeutics and its competitors.
Is Vivos Therapeutics' Beginning Cash Position too high?
Vivos Therapeutics' current Beginning Cash Position is $2.03 Mil. Overall, Vivos Therapeutics has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vivos Therapeutics' Beginning Cash Position compare to XAIR and TNON?
Vivos Therapeutics' Beginning Cash Position of $2.03 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Medical Devices & Instruments company?
A good Beginning Cash Position depends on the Medical Devices & Instruments industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Vivos Therapeutics and its competitors. Vivos Therapeutics's current Beginning Cash Position is $2.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Vivos Therapeutics (VVOS) is currently considered Possible Value Trap. The stock's GF Value™ is $1.15, compared to a current price of $0.48 — trading 58.3% below its estimated fair value. The current Beginning Cash Position is $2.03 Mil. Vivos Therapeutics' overall GF Score™ is 43/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Vivos Therapeutics (VVOS), the current Beginning Cash Position is $2.03 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vivos Therapeutics (VVOS) Overvalued in 2026?

Based on GuruFocus' analysis, Vivos Therapeutics stock appears to be undervalued. The current stock price of $0.48 is trading 58.3% below its estimated GF Value™ of $1.15. GuruFocus considers Vivos Therapeutics to be Possible Value Trap.

Key valuation signals for VVOS:

  • Beginning Cash Position: $2.03 Mil
  • GF Value™: $1.15 vs. price of $0.48 (58.3% below fair value)
  • GF Score™: 43/100 with 6 warning signs

No single metric tells the full story. See the VVOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vivos Therapeutics Business Description

Address 7921 Southpark Plaza, Suite 210, Littleton, CO, USA, 80120
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
43GF Score

Get the complete analysis for VVOS

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.48
Price
$1.15
GF Value